Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients with metastatic colorectal cancer using first-line nivolumab. Choosing the ...
TAS-102 plus bevacizumab is cost-effective in China but not in the US or UK due to high incremental cost-effectiveness ratios (ICERs). The study uses a decision model to compare TAS-102 monotherapy ...
Outcomes including local recurrence, distant metastases, and survival as well as toxicity data were modeled by a patient-level Markov microsimulation model, which were validated against trial data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results